• LAST PRICE
    0.7842
  • TODAY'S CHANGE (%)
    Trending Down-0.0208 (-2.5839%)
  • Bid / Lots
    0.7807/ 4
  • Ask / Lots
    0.7825/ 2
  • Open / Previous Close
    0.7910 / 0.8050
  • Day Range
    Low 0.7731
    High 0.7911
  • 52 Week Range
    Low 0.5510
    High 63.8500
  • Volume
    220,811
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 0.805
TimeVolumeNRBO
09:32 ET80800.791
09:33 ET5000.791
09:35 ET122020.7801
09:37 ET266560.7737
09:39 ET44500.78
09:42 ET269210.788
09:44 ET9940.7772
09:46 ET33110.78
09:48 ET11080.780001
09:50 ET7750.7827
09:51 ET16710.78
09:55 ET61500.78
09:57 ET11000.784
10:04 ET10000.787899
10:08 ET18680.7821
10:11 ET4000.7807
10:13 ET53000.788
10:15 ET13370.7843
10:18 ET25000.787821
10:20 ET2160.784501
10:22 ET25000.7879
10:24 ET1000.788
10:27 ET10000.7837
10:29 ET48000.788
10:33 ET92590.788
10:36 ET10000.7813
10:38 ET5700.788
10:40 ET6000.788
10:45 ET5000.781
10:47 ET40000.7879
10:49 ET15000.782
10:51 ET20100.7837
10:56 ET10000.788
11:00 ET2710.781101
11:02 ET41300.78455
11:03 ET39480.780857
11:07 ET23260.7834
11:09 ET13000.7842
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNRBO
Neurobo Pharmaceuticals Inc
15.3M
-0.1x
---
United StatesNERV
Minerva Neurosciences Inc
15.4M
-0.3x
---
United StatesCNTX
Context Therapeutics Inc
15.5M
-1.0x
---
United StatesRCAR
RenovaCare Inc
15.7M
-4.4x
---
United StatesERNA
Eterna Therapeutics Inc
14.8M
-0.5x
---
United StatesCUBT
Curative Biotechnology Inc
15.3M
-92.9x
---
As of 2023-02-08

Company Information

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies. The Company is engaged in providing therapeutic programs designed to impact a range of indications in coronavirus, neurodegenerative and cardiometabolic disease. Its products include ANA001, Niclosamide, NB-01 and NB-02. The ANA001 is an oral niclosamide formulation and is being developed as a treatment for patients with moderate coronavirus disease. Niclosamide is a potential oral antiviral and anti-inflammatory agent and being studied in a 60-subject Phase II clinical trial conducted in the United States. NB-01 primarily focused on the development of a treatment for painful diabetic neuropathy (PDN). NB-02 has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid beta plaque deposition.

Contact Information

Headquarters
200 BERKELEY ST., FL 19BOSTON, MA, United States 02116
Phone
857-702-9600
Fax
734-293-0444

Executives

Independent Chairman of the Board
Andrew Koven
President, Interim Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer
Joseph Hooker
Senior Vice President - Operations
Matthew Bardin
Director
Jeong Gu Kang
Independent Director
Jason Groves

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$15.3M
Revenue (TTM)
$0.00
Shares Outstanding
19.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.15
EPS
$-15.64
Book Value
$16.43
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.